Rosiglitazone: a European regulatory perspective.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies.BMC cardiovascular disorders · 2014 · on this map
   Pooled it
2. Discovery by Virtual Screening of an Inhibitor of CDK5-Mediated PPARγ Phosphorylation.ACS medicinal chemistry letters · 2022
   Article
3. Future Perspective of Diabetic Animal Models.Endocrine, metabolic & immune disorders drug targets · 2020
   Review
4. Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations.Diabetes, obesity & metabolism · 2018
   Review
5. The European Medicines Agency's approval of new medicines for type 2 diabetes.Diabetes, obesity & metabolism · 2018
   Review
6. A Data-Driven Approach to Predicting Successes and Failures of Clinical Trials.Cell chemical biology · 2016
   Article
7. Insights from cardiovascular outcome trials with novel antidiabetes agents: what have we learned? An industry perspective.Current diabetes reports · 2015
   Review
8. β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes.World journal of diabetes · 2015
   Review
9. Identifying plausible adverse drug reactions using knowledge extracted from the literature.Journal of biomedical informatics · 2014
   Article
10. Importance of Beta Cell Function for the Treatment of Type 2 Diabetes.Journal of clinical medicine · 2014
    Review
11. Developmental and extracellular matrix-remodeling processes in rosiglitazone-exposed neonatal rat cardiomyocytes.Pharmacogenomics · 2014
    Article
12. Rosiglitazone use and post-discontinuation glycaemic control in two European countries, 2000-2010.BMJ open · 2013
    Article
13. Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside.Cellular and molecular life sciences : CMLS · 2013
    Review
14. Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.Drug safety · 2012
    Article
15. PPARγ activator, rosiglitazone: Is it beneficial or harmful to the cardiovascular system?World journal of cardiology · 2011
    Article
16. Tenofovir nephrotoxicity: 2011 update.AIDS research and treatment · 2011
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as